The Performances of Conventional Titanium and Silver-Coated Megaprostheses in Non-oncological and Post-oncological Patients: An Analysis of Infection Failures in 142 Patients

Document Type : RESEARCH PAPER


1 Department of Orthopaedic and Trauma Surgery, University of Pisa, Italy

2 Department of Ophtalmology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy

3 Department of Oncology and Surgery at Robotic Address of the Hospital Careggi University of Florence, Firenze FI, Italy

4 Department of Orthopaedic and Trauma Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland


Background: Megaprostheses are one of the preferred choices of reconstruction after tumor resection. Periprosthetic 
joint infections are one of the most serious complications of joint prostheses surgeries. In this study, our aim was to 
analyze the efficacy of silver-coated megaprostheses in reducing the risk of prosthesis-related infection.
Methods: One hundred forty-two patients who had undergone implantation of a mega-endoprosthesis for nonneoplastic or post-neoplastic conditions were included in this retrospective study. The end-point of the survival analysis 
was the prosthesis failure due to infection. 
Results: Thirty-eight patients had undergone implantation of a silver-coated megaprosthesis and 104 patients a 
megaprosthesis without silver coating. The survival analysis showed an overall infection-free survival rate of 82.3% at 
five years and 61.9% at 10 years. Silver-coated prostheses had an HR of 0.72 (95% CI: 0.26-2.05; P=0.54).
Conclusion: Implantation of a silver-coated mega-prosthesis in non-oncological patients did not significantly reduce 
the risk of prosthesis-related infection.
Level of evidence: III


1. Malawer MM, Henshaw RM, Kellar-Graney K.
Overview of Endoprosthetic Reconstruction.
Operative Techniques in Orthopaedic Surgical
Oncology. 2012:34-45.
2. Gkavardina A, Tsagozis P. The use of megaprostheses
for reconstruction of large skeletal defects in
the extremities: a critical review. Open Orthop J.
3. Al-Taki MM, Masri BA, Duncan CP, Garbuz DS. Quality
of life following proximal femoral replacement using
a modular system in revision THA. Clin Orthop Relat
Res. 2011; 469(2):470-5.
4. Alvand A, Grammatopoulos G, de Vos F, Scarborough M,
Kendrick B, Price A, et al. Clinical Outcome of Massive
Endoprostheses Used for Managing Periprosthetic
Joint Infections of the Hip and Knee. J Arthroplasty.
5. Artiaco S, Boggio F, Colzani G, Titolo P, Zoccola K,
Bianchi P, et al. Megaprostheses in the Revision
of Infected Total Hip Arthroplasty. Clinical Series and Literature Review. Bull Hosp Jt Dis (2013).
6. De Gori M, Scoccianti G, Frenos F, Bettini L, Familiari
F, Gasparini G, et al. Modular Endoprostheses for
Nonneoplastic Conditions: Midterm Complications
and Survival. Biomed Res Int. 2016;2016:2606521.
7. Bettin CC, Weinlein JC, Toy PC, Heck RK. Distal Femoral
Replacement for Acute Distal Femoral Fractures in
Elderly Patients. J Orthop Trauma. 2016;30(9):503-9.
8. Calori GM, Colombo M, Malagoli E, Mazzola S, Bucci
M, Mazza E. Megaprosthesis in post-traumatic and
periprosthetic large bone defects: Issues to consider.
Injury. 2014;45 Suppl 6:S105-10.
9. Evans S, Laugharne E, Kotecha A, Hadley L, Ramasamy
A, Jeys L. Megaprostheses in the management of
trauma of the knee. J Orthop. 2015;13(4):467-471.
10.Korim MT, Esler CN, Reddy VR, Ashford RU. A
systematic review of endoprosthetic replacement for
non-tumour indications around the knee joint. Knee.
11.Korim MT, Esler CN, Ashford RU. Systematic review
of proximal femoral arthroplasty for non-neoplastic
conditions. J Arthroplasty. 2014;29(11):2117-21.
12.Schoenfeld AJ, Leeson MC, Vrabec GA, Scaglione
J, Stonestreet MJ. Outcomes of modular proximal
femoral replacement in the treatment of complex
proximal femoral fractures: a case series. Int J Surg.
13.Toepfer A, Harrasser N, Petzschner I, Pohlig F, Lenze U,
Gerdesmeyer L, et al. Short- to long-term follow-up of
total femoral replacement in non-oncologic patients.
BMC Musculoskelet Disord. 2016;17(1):498.
14.Vasso M, Beaufils P, Cerciello S, Schiavone Panni A.
Bone loss following knee arthroplasty: potential
treatment options. Arch Orthop Trauma Surg.
15.Windhager R, Schreiner M, Staats K, Apprich S.
Megaprostheses in the treatment of periprosthetic
fractures of the knee joint: indication, technique,
results and review of literature. Int Orthop.
16.De Gori M, Gasparini G, Capanna R. Risk Factors for
Perimegaprosthetic Infections After Tumor Resection.
Orthopedics. 2017;40(1):e11-e16.
17.George DA, Gant V, Haddad FS. The management
of periprosthetic infections in the future: a review
of new forms of treatment. Bone Joint J. 2015;97-
18.Osmon DR. Microbiology and Antimicrobial
Challenges of Prosthetic Joint Infection. J Am Acad
Orthop Surg. 2017; 25 Suppl 1:S17-S19.
19.Tande AJ, Patel R. Prosthetic joint infection. Clin
Microbiol Rev. 2014;27(2):302-45.
20.Tande AJ, Gomez-Urena EO, Berbari EF, Osmon DR.
Management of Prosthetic Joint Infection. Infect Dis
Clin North Am. 2017;31(2):237-252.
21.Haijie L, Dasen L, Tao J, Yi Y, Xiaodong T, Wei G. Implant
Survival and Complication Profiles of Endoprostheses
for Treating Tumor Around the Knee in Adults: A
Systematic Review of the Literature Over the Past 30
Years. J Arthroplasty. 2018;33(4):1275-1287.e3.
22.Henderson ER, Groundland JS, Pala E, Dennis JA,
Wooten R, Cheong D, et al. Failure mode classification
for tumor endoprostheses: retrospective review of
five institutions and a literature review. J Bone Joint
Surg Am. 2011;93(5):418-29.
23.Alt V. Antimicrobial coated implants in trauma and
orthopaedics-A clinical review and risk-benefit
analysis. Injury. 2017;48(3):599-607.
24.Gallo J, Holinka M, Moucha CS. Antibacterial surface
treatment for orthopaedic implants. Int J Mol Sci.
25.Spanish. Ezquerra AA, Bona AP. Uso de recubrimientos
protésicos de plata en cirugí�a tumoral: influencia en
la tasa de infección. Revista de la Facultad de Ciencias
Médicas de Córdoba. 2017;74(3):239-242.
26.Cheng H, Li Y, Huo K, Gao B, Xiong W. Long-lasting in
vivo and in vitro antibacterial ability of nanostructured
titania coating incorporated with silver nanoparticles.
J Biomed Mater Res A. 2014;102(10):3488-99.
27.Donati F, Di Giacomo G, D’Adamio S, Ziranu A, Careri
S, Rosa M, et al. Silver-Coated Hip Megaprosthesis in
Oncological Limb Savage Surgery. Biomed Res Int.
28.Hardes J, Henrichs MP, Hauschild G, Nottrott M, Guder
W, Streitbuerger A. Silver-Coated Megaprosthesis
of the Proximal Tibia in Patients With Sarcoma. J
Arthroplasty. 2017;32(7):2208-2213.
29.Schmidt-Braekling T, Streitbuerger A, Gosheger G,
Boettner F, Nottrott M, Ahrens H, et al. Silver-coated
megaprostheses: review of the literature. Eur J Orthop
Surg Traumatol. 2017;27(4):483-489.
30.Schmolders J, Koob S, Schepers P, Pennekamp PH,
Gravius S, Wirtz DC, et al. Lower limb reconstruction
in tumor patients using modular silver-coated
megaprostheses with regard to perimegaprosthetic
joint infection: a case series, including 100 patients
and review of the literature. Arch Orthop Trauma
Surg. 2017;137(2):149-153.
31.Streitbuerger A, Henrichs MP, Hauschild G, Nottrott
M, Guder W, Hardes J. Silver-coated megaprostheses
in the proximal femur in patients with sarcoma. Eur J
Orthop Surg Traumatol. 2019;29(1):79-85.
32.Sambri A, Zucchini R, Giannini C, Zamparini E,
Viale P, Donati DM, et al. Silver-coated (PorAg®)
endoprosthesis can be protective against reinfection
in the treatment of tumor prostheses infection. Eur J
Orthop Surg Traumatol. 2020;30(8):1345-1353.
33.Fiore M, Sambri A, Zucchini R, Giannini C, Donati DM, De
Paolis M. Silver-coated megaprosthesis in prevention
and treatment of peri-prosthetic infections: a
systematic review and meta-analysis about efficacy
and toxicity in primary and revision surgery. Eur J
Orthop Surg Traumatol. 2021;31(2):201-220.
34.Parry MC, Laitinen MK, Albergo JI, Gaston CL,
Stevenson JD, Grimer RJ, et al. Silver-coated (Agluna®)
tumour prostheses can be a protective factor against
infection in high risk failure patients. Eur J Surg Oncol.
35.Scoccianti G, Frenos F, Beltrami G, Campanacci DA,
Capanna R. Levels of silver ions in body fluids and
clinical results in silver-coated megaprostheses after tumour, trauma or failed arthroplasty. Injury. 2016;47
Suppl 4:S11-S16.
36.Wafa H, Grimer RJ, Reddy K, Jeys L, Abudu A, Carter
SR, et al. Retrospective evaluation of the incidence
of early periprosthetic infection with silver-treated
endoprostheses in high-risk patients: case-control
study. Bone Joint J. 2015;97-B(2):252-7.
37.Zajonz D, Birke U, Ghanem M, Prietzel T, Josten C, Roth
A, et al. Silver-coated modular Megaendoprostheses
in salvage revision arthroplasty after periimplant
infection with extensive bone loss - a pilot study of 34
patients. BMC Musculoskelet Disord. 2017;18(1):383. 
Volume 10, Issue 5
May 2022
Pages 439-446
  • Receive Date: 25 June 2021
  • Revise Date: 13 October 2021
  • Accept Date: 11 November 2021
  • First Publish Date: 15 November 2021